Biomarkers in oncology: Trials and tribulations

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 111-118

  Taube, Sheila E ^a  

^a ST Consulting   (United States)

Author keywords

Biomarker assay development; Oncology biomarkers; Predictive markers

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOASSAY; BREAST CANCER; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE MARKER; FOOD AND DRUG ADMINISTRATION; HUMAN; ONCOLOGY; PATIENT CARE; PRACTICE GUIDELINE; RELIABILITY; REPRODUCIBILITY; SCREENING; TUMOR GROWTH;

BIOLOGICAL MARKERS; HUMANS; NEOPLASMS;

EID: 70449372168     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05019.x     Document Type: Conference Paper

References (23)

1. Gold, P. & S.O. Freedman. 1965. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121: 439-462.
2. Thompson,D., J. Krupey, S.O. Freedman, et al. 1969. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl. Acad. Sci. USA 64: 161-167.
3. Conley, B.A. & S.E. Taube. 2004. Prognostic and predictive markers in cancer. Disease Markers 20: 35-43.
4. Lesko, L.J. 2007. Personalized medicine: elusive dream or imminent reality? Clin. Pharm. Ther. 81: 807-816.
5. Harris, L., H. Fritsche, R.Mennel, et al. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25: 5287-5312. (Pubitemid 350232263)
6. Locker, G.Y., S. Hamilton, J. Harris, et al. 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24: 5313-5327.
7. O'Brien, S.G., F. Guilhot, R.A. Larson, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004.
8. Andriole, G.L., E.D. Crawford, R.L. Grubb III, et al. 2009. Mortality results from a randomized prostatecancer screening trial. N. Engl. J. Med. 360: 1310-1319.
9. Schr̈oder, F.H., J. Hugosson, M.J. Roobol, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360: 1320-1328.
10. http://www.fda.gov/cdrh/oivd/guidance/1610.pdf in vitro diagnostic multivariate index assays Draft guidance.
11. McShane, L.M., D.G. Altman, W. Sauerbrei, et al. 2005. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2: 416-422 (same article published simultaneously in JNCI, EJC, JCO, and BJC). (Pubitemid 43115010)
12. Hakimian, R., S. Taube, M. Bledsoe, et al. 2005. 50- State survey of laws regulating the collection, storage, and use of human tissue specimens and associated data for research. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute.
13. http://cdp.cancer.gov/assessment/progress/remark.htm Remark checklist and text.
14. http://cdp.cancer.gov/pdf/PACCT-Assay-Standards-Document.pdf
15. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf Breast cancer treatment guidelines.
16. Fisher, B., J. Dignam, N. Wolmark, et al. 1997. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89: 1673-1682.
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials. Lancet 365: 1687-1717.
18. Cronin, M., M. Pho, D. Dutta, et al. 2004. Measurement of gene expression in archival paraffinembedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 164: 35-42.
19. Paik, S., S. Shak,G. Tang, et al. 2004. Amultigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N. Engl. J. Med. 351: 2817-2826.
20. Paik, S., G. Tang, S. Shak, et al. 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3726-3734.
21. http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1 Information about TAILORx trial.
22. Taube, S. & J. Abrams. 2005. Program for the assessment of clinical cancer tests (PACCT): assisting development of tailored cancer therapy. Per. Med. 2: 363-369.
23. Taube, S., J. Jacobson & T. Lively. 2005. Cancer diagnostics decision criteria for marker utilization in the clinic. Am. J. Pharmacogenomics 5: 357-364.